Education
About Us
Working with TipRanks
Follow Us
Cryosite Limited (AU:CTE)
ASX:CTE
CTE Stock Chart & Stats
AU$1.00
-AU$0.05(-6.02%)
At close: 4:00 PM EST
AU$1.00
-AU$0.05(-6.02%)
Day’s Range― - ―
52-Week RangeAU$0.60 - AU$1.30
Previous CloseN/A
Volume1.46K
Average Volume (3M)1.97K
Market Cap
AU$51.74M
Enterprise ValueAU$48.95M
Total Cash (Recent Filing)AU$5.06M
Total Debt (Recent Filing)AU$2.27M
Price to Earnings (P/E)27.5
Beta-0.83
Next Earnings
Feb 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio8.08
Price to Book (P/B)15.22
Price to Sales (P/S)2.58
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained high gross (62.98%) and solid net margins imply durable pricing power and efficient service delivery in biobanking. These margins support reinvestment in compliance and capacity, provide a cushion against cost shocks, and underpin long-term profitability of the core business.
Recurring Revenue ModelA business model based on upfront processing plus annual storage fees creates predictable, recurring revenue and higher customer lifetime value. That steady cash inflow supports capex and regulatory compliance, making growth and planning more resilient over the medium term.
Very Strong Return On EquityROE near 79% indicates management is generating high returns on shareholders' capital, reflecting efficient operations and profitable deployment of equity. Sustained high ROE can fund growth internally and signals competitive operational execution in its niche.
Bears Say
Declining Free Cash Flow GrowthA >30% drop in free cash flow growth and operating cash flow below net income indicate weakening cash conversion. This constrains the firm's ability to self-fund expansion, meet rising compliance costs, or absorb shocks, increasing reliance on external financing over months.
Elevated Leverage And Low Equity RatioDebt-to-equity near 1 and a low equity ratio mean meaningful leverage for a small biobanking operator. Combined with weakening free cash flow, this raises refinancing and interest-service risk and limits strategic flexibility for capex or M&A over the medium term.
Small Operational ScaleA headcount of 25 indicates limited operational scale relative to broader market opportunity. Small scale can constrain capacity to expand networks, manage complex regulatory demands, and commercialise partnerships, requiring investment to capture growing regenerative medicine demand reliably.
Cryosite Limited News
CTE FAQ
What was Cryosite Limited’s price range in the past 12 months?
Cryosite Limited lowest share price was AU$0.60 and its highest was AU$1.30 in the past 12 months.
What is Cryosite Limited’s market cap?
Cryosite Limited’s market cap is AU$51.74M.
When is Cryosite Limited’s upcoming earnings report date?
Cryosite Limited’s upcoming earnings report date is Feb 19, 2026 which is in 15 days.
How were Cryosite Limited’s earnings last quarter?
Cryosite Limited released its earnings results on Aug 21, 2025. The company reported AU$0.021 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.021.
Is Cryosite Limited overvalued?
According to Wall Street analysts Cryosite Limited’s price is currently Overvalued.
Does Cryosite Limited pay dividends?
Cryosite Limited pays a Annually dividend of AU$0.02 which represents an annual dividend yield of N/A. See more information on Cryosite Limited dividends here
What is Cryosite Limited’s EPS estimate?
Cryosite Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cryosite Limited have?
Cryosite Limited has 48,809,563 shares outstanding.
What happened to Cryosite Limited’s price movement after its last earnings report?
Cryosite Limited reported an EPS of AU$0.021 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Cryosite Limited?
Currently, no hedge funds are holding shares in AU:CTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryosite Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
98.18%
Trailing 12-Months
Asset Growth
-1.26%
Trailing 12-Months
Company Description
Cryosite Limited
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---